#None #AstraZeneca #Cambridge, Massachusetts #biotherapeutics #Harbour BioMed

Harbour BioMed and AstraZeneca Strengthen Partnership

Harbour BioMed (HKEX: 02142), a leading global biopharmaceutical firm, has recently updated its strategic collaboration with AstraZeneca, a major player in the pharmaceutical industry. This multi-faceted alliance, which originated in March 2025, seeks to accelerate the discovery and development of novel biotherapeutics, primarily in the field of oncology.

Strategic Vision

The primary focus of this collaboration is the development of next-generation therapeutic options, including antibody-drug conjugates (ADCs) and T cell engagers. Both companies aim to harness their unique strengths and knowledge to create innovative treatments that address pressing medical needs. AstraZeneca will propose multiple discovery programs to Harbour BioMed over the coming four years, emphasizing a joint commitment to advancing biotherapeutics.

Dr. Jingsong Wang, the visionary CEO and Founder of Harbour BioMed, expressed enthusiasm regarding the partnership's progress. He emphasized the solid trust and rapport established between the two entities since they began working together in 2022. This collaboration not only enhances their research and development capabilities but also increases their potential to meet unmet medical needs globally.

A Win-Win Pact

As part of the deal, AstraZeneca retains the right to license these new discovery programs for further development. For each licensed program, Harbour BioMed stands to gain development and commercial milestone payments, in addition to tiered royalties based on future net sales. This economic arrangement aligns with the financial model established during the partnership’s inception in March 2025.

Harbour BioMed’s Innovative Technological Advantage

Harbour BioMed has made notable advancements in antibody technology, primarily through its proprietary Harbour Mice® platform. This technology allows for the efficient creation of fully human monoclonal antibodies in various formats—a significant achievement in the field. Moreover, by developing HCAb-based immune cell engagers (called HBICE®) and bispecific immune cell antagonists (HBICATM), Harbour BioMed is positioned to produce innovative biologics capable of addressing both oncological and immunological challenges.

Impact on Cancer Treatment

The innovative synergy between Harbour BioMed and AstraZeneca is set to revolutionize cancer therapies. Early results signal promising developments that hold the potential not just for improved treatment efficacy but also better patient outcomes. The commitment to discover one-of-a-kind biotherapeutic solutions reflects the pressing need for advancements in oncology.

With a foundation built upon R&D investments, strategic global partnerships, and selective acquisitions, Harbour BioMed aligns its objectives with humanitarian goals, aiming to enhance the quality of life for patients around the world.

Future Exploration

As this collaboration unfolds, it is clear that both Harbour BioMed and AstraZeneca are dedicated to remaining at the forefront of biopharmaceutical innovation. The focus on next-generation antibody therapeutics signifies a commitment to understanding and addressing critical health issues that affect millions.

For more information about Harbour BioMed and its innovative programs, visit their official website: www.harbourbiomed.com.